Carlo Maley, PhD, Arizona State University, Tempe, AZ, outlines parameters that affect the evolution rate, highlighting methods available to measure neoplasm evolution, and explaining how we can use this knowledge to predict disease progression and relapse as well as resistance to therapies in chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.